Autolus Therapeutics (FRA:6A3A) Short Interest


FRA:6A3A Autolus Therapeutics PLC FRA:6A3A
68 GF Score
Price €1.37
GF Value €16.88
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Autolus Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:6A3A vs FBRX, SGMT, EDIT: Short Interest Comparison

For the Biotechnology subindustry, Autolus Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Autolus Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Autolus Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Autolus Therapeutics's Short Interest falls into.


FRA:6A3A
68GF Score
Autolus Therapeutics PLC FRA:6A3A
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Autolus Therapeutics (FRA:6A3A) Overvalued in 2026?

Based on GuruFocus' analysis, Autolus Therapeutics stock appears to be undervalued. The current stock price of €1.37 is trading 91.9% below its estimated GF Value™ of €16.88. GuruFocus considers Autolus Therapeutics to be Possible Value Trap.

Key valuation signals for FRA:6A3A:

  • Short Interest:
  • GF Value™: €16.88 vs. price of €1.37 (91.9% below fair value)
  • GF Score™: 68/100 with 7 warning signs

No single metric tells the full story. See the FRA:6A3A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Autolus Therapeutics Business Description

Other Exchanges AUTL:USA6A3A:Germany
Address 191 Wood Lane, The MediaWorks, London, GBR, W12 7FP
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
68GF Score

Get the complete analysis for FRA:6A3A

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.37
Price
€16.88
GF Value